Anti-nail fungus / photosensitive drug nail penetration delivery carrier based on transfersome as well as preparation method and application of anti-nail fungus / photosensitive drug nail penetration delivery carrier

By packaging photosensitizers in anti-alpha fungi drugs and using transmitter technology, nanotransmitters that can penetrate deeply into the deck are prepared, which solves the problems of drug resistance and high recurrence rate of anti-alpha fungi drugs, and achieves efficient treatment Effects and safety.

CN118903014APending Publication Date: 2024-11-08XI AN JIAOTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411033972.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the prior art, local treatment of anti-alpha fungi drugs has problems with high drug resistance and recurrence rates, and photosensitizers are difficult to fully penetrate the infected parts of the diseased aphrodisiac, resulting in low treatment efficiency.

Method used

Using an anti-alkali fungus/photosensitive drug permeable delivery vehicle based on the transfer body, the nanoparticles composed of phospholipids, cholesterol and edge activators are used to rotate evaporate and ultrasonic hydration, etc. Methods are prepared to form a nanotransmitter formulation that can penetrate deeply into the deck.

Benefits of technology

It improves the permeability and bioavailability of drugs, reduces disease recurrence and drug resistance, shortens the treatment cycle, and achieves the penetration and effect of photosensitizers without pretreatment of diseased anaerobics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903014A_ABST
    Figure CN118903014A_ABST
Patent Text Reader

Abstract

The invention discloses an anti-nail fungus / photosensitive medicine nail penetrating delivery carrier based on a carrier as well as a preparation method and application thereof, and belongs to the field of pharmaceutical preparations. Comprising the following main steps: dissolving phospholipid, cholesterol, a surfactant, an antifungal drug and / or a photosensitizer in an organic phase, carrying out rotary evaporation at a temperature higher than a lipid phase transition temperature to remove an organic solvent so as to obtain a lipid film, adding a proper amount of a solution (a proper ratio of a phosphate buffer solution to ethanol), carrying out rotary hydration, and carrying out freeze-drying so as to obtain the lipid film. And finally, extruding the obtained solution to the required particle size by using a polycarbonate film. By optimizing the variety and content of each component, the suspension of the nano-carrier for treating the onychomycosis is prepared. Experimental results show that the preparation process of the transfersome preparation provided by the invention is simple, and the transfersome preparation is non-irritant to a human body; the nail penetrating performance is good, the nail penetrating agent can penetrate through a deck and penetrate into subnail tissues to play an antifungal role, and the treatment effect on nail mycosis is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of pharmaceutical preparations, and in particular relates to a transfersome-based anti-nail fungus / photosensitive drug nail-penetrating delivery carrier and a preparation method and application thereof. Background Art

[0002] Onychomycosis refers to a disease caused by dermatophytes, yeasts, and non-dermatophyte fungi invading the nail plate and / or nail bed. Onychomycosis caused by dermatophytes is usually called onychomycosis. The incidence of onychomycosis accounts for 2% to 18% of the natural population. The incidence of onychomycosis is related to age, gender, and site. The incidence is higher in the elderly, higher in men than in women, more common in toenails than in fingernails, and higher in the incidence of big toenails than in other nails. At present, the systemic treatment of onychomycosis mainly relies on oral antifungal drugs, but these drugs still have some problems in treatment, including long medication cycles, poor patient compliance, adverse drug reactions and drug interaction risks, and the possibility of drug resistance. Although local treatment drugs have few adverse reactions and low drug interaction risks, local treatment is still subject to certain limitations due to problems such as difficulty in drug penetration of the nail plate, low treatment efficiency, and high recurrence rate. Therefore, the demand for new treatment methods is increasing.

[0003] Transfersomes, also known as flexible liposomes, are mainly composed of phospholipids, cholesterol and membrane softeners. Alcohol transfersomes are new vesicle carriers developed by adding a certain amount of ethanol to the formula of transfersomes. They have two regions, lipophilic and hydrophilic, and can accommodate drug molecules with a wide range of solubility. The membrane softener in the transfersome is a single-chain surfactant that can increase the fluidity and flexibility of the membrane. After external use, it can easily penetrate into the stratum corneum and nail plate through extrusion and deformation, and release the encapsulated drugs into the subungual tissue and even into the blood circulation. Transfersomes have excellent properties such as low toxicity, biocompatibility, and sustained release, and can increase the amount of drugs that penetrate the nail and the amount of drugs that are retained. It is a new treatment idea.

[0004] Photodynamic therapy is a non-invasive treatment method that uses non-toxic photosensitizers, visible or near-infrared light of a specific wavelength, and molecular oxygen around or inside pathogens to produce phototoxic reactions to kill pathogens. These active oxygen species cause irreversible oxidative damage to the biomacromolecules and cell structures of pathogens, leading to the death of pathogens. It has high selectivity, high safety, and no drug resistance. It shows good clinical application prospects in the local treatment of onychomycosis.

[0005] Although transfersomes are the most effective transdermal drug nano-delivery carriers, there are currently no reports of transfersomes with good nail penetration and the ability to penetrate deeply into the nail plate; and local drugs used to treat onychomycosis have problems such as drug resistance and high recurrence rates; and there are still few clinical studies on photodynamic therapy for onychomycosis, mainly because it is difficult for photosensitizers to fully penetrate into the infected area of ​​the diseased nail, and they need to be pre-treated such as cutting, polishing, and softening to achieve better results. Summary of the invention

[0006] In order to overcome the shortcomings of the above-mentioned prior art, the purpose of the present invention is to provide a transfersome-based anti-onychomycosis / photosensitive drug transungual delivery carrier and its preparation method and application, so as to solve the problems of drug resistance and high recurrence rate of existing local drugs, and to fill the current research and development gap in antibacterial drugs for onychomycosis that have not yet been applied in combination with photosensitizers and transfersomes.

[0007] In order to achieve the above object, the present invention adopts the following technical solutions:

[0008] The present invention provides a transfersome-based anti-nail fungus / photosensitive drug trans-nail delivery carrier, which is prepared from raw materials containing the following molar fractions: 0-10.0 parts of anti-nail fungus drug, 0-10.0 parts of photosensitizer, 6.0-30.0 parts of phospholipid, 0-2.0 parts of cholesterol, and 0-8.0 parts of edge activator; wherein the anti-nail fungus drug and the photosensitizer cannot be 0 at the same time.

[0009] As a further improvement of the technical solution of the present invention, the transfersome is prepared from raw materials containing the following molar fractions: 10.0 parts of antifungal drugs and / or photosensitizers, 8.0 parts of phospholipids, 0.5 parts of cholesterol, and 4.0 parts of edge activators.

[0010] As a further improvement of the technical solution of the present invention, the antifungal drug is selected from one or more of ciclopirox, amorolfine, conazole drugs, tazarotene and tavaborole, and can be further adjusted according to the specific typing of nail fungi.

[0011] As a further improvement of the technical solution of the present invention, the photosensitizer is selected from one or more of hematoporphyrin monomethyl ether, aloe-emodin, curcumin, and alafenamide, and can be further adjusted according to the specific typing of nail fungi.

[0012] As a further improvement of the technical solution of the present invention, the phospholipid is selected from one or more of dipalmitoylphosphatidylcholine, (2,3-dioleoyl-propyl)-trimethylamine, phosphatidic acid, phosphatidylserine, soybean lecithin and egg yolk lecithin;

[0013] Furthermore, soybean lecithin is preferred.

[0014] As a further improvement of the technical solution of the present invention, the edge activator is selected from one or more of Tween, sodium cholate and sodium deoxycholate;

[0015] Furthermore, sodium deoxycholate is preferred.

[0016] Furthermore, the Tween is Tween 20, Tween 60 or Tween 80.

[0017] The present invention also provides a method for preparing the above-mentioned transfersome preparation for onychomycosis based on photodynamic therapy, the preparation method comprising the following steps:

[0018] 1) dissolving the antifungal drug and / or photosensitizer, phospholipid, cholesterol, and edge activator in an organic solvent to obtain a mixture;

[0019] 2) rotary evaporating the organic solvent in the mixture to obtain a mixture film;

[0020] 3) adding a hydrating medium to the mixture film for ultrasonic hydration and annealing to obtain a primary drug solution;

[0021] 4) The primary drug solution is homogenized to obtain the transfersome preparation.

[0022] Furthermore, in step 1), the organic solvent is selected from one or more of methanol, chloroform, and ethanol, preferably methanol and chloroform; the antifungal drug and / or photosensitizer, edge activator are dissolved in methanol, and the phospholipid and cholesterol are dissolved in chloroform.

[0023] In step 2), the mixture is rotary evaporated under vacuum conditions in water at 35°C to 65°C.

[0024] In step 2), the mixture is rotary evaporated at a speed of 100 to 120 r / min.

[0025] In step 3), the hydration method is ultrasonic treatment, the hydration temperature is 45° C. in water, and the annealing method is standing at room temperature.

[0026] In step 3), the hydration medium is a mixture of phosphate buffer solution and ethanol, wherein the proportion of ethanol is 0% to 35%.

[0027] In step 4), the obtained primary drug solution is homogenized by a polycarbonate membrane having a diameter of 100 to 400 nm to obtain a transfersome for treating onychomycosis.

[0028] Polycarbonate film, usually referred to as PC film, is a film made of polycarbonate resin as the base material. PC film has extremely high transparency, its light transmittance can exceed 90%, and its haze is less than 0.2%. It is an excellent light-transmitting material. The thickness of PC film is generally between 0.15mm and 3mm. When the thickness is less than or equal to 0.25mm, it is usually called a film.

[0029] Furthermore, the diameter of the polycarbonate membrane in step 4) is preferably 200 nm.

[0030] In addition to the above methods, the transfersome preparation for treating onychomycosis of the present invention can also be prepared according to other conventional methods for preparing transfersomes and alcohol transfersome preparations in the art.

[0031] The present invention also provides the use of the above-mentioned transfersome-based anti-onychomycosis / photosensitive drug trans-nail delivery carrier in drugs for treating onychomycosis: mainly used for local (including photodynamic) treatment of onychomycosis.

[0032] The present invention also provides an external preparation for onychomycosis, which is prepared by adding or not adding pharmaceutically acceptable excipients to the above-mentioned transfersome preparation for onychomycosis based on photodynamic therapy;

[0033] Furthermore, the transfersome preparation is an external preparation, preferably a transdermal administration preparation.

[0034] Compared with the prior art, the present invention has the following beneficial effects:

[0035] The anti-onychia / photosensitive drug nail-penetrating delivery carrier based on a transfersome disclosed in the present invention has the advantages that, on the one hand, the lipid bilayer structure composed of lipids, marginal active agents and ethanol in the formula can be assembled into nanoparticles, which can accommodate drug molecules with a wide range of solubility compared to single-phase solvent systems and general transfersomes, and are more likely to penetrate the nail plate and smoothly enter the subungual tissue to kill pathogens; on the other hand, since it is difficult for second-generation photosensitizers to fully penetrate the infected part of diseased nails, it is necessary to perform pretreatments such as cutting, polishing and softening on the diseased nails to obtain better treatment effects, the photosensitizer is packaged into the nail-penetrating delivery carrier in the present invention, and the photosensitizer can penetrate the nail plate and enter the subungual tissue without pretreatment of the diseased nails, thereby accumulating in rapidly multiplying pathogens, and the location of the phototoxic reaction can be selectively controlled by controlling the illumination area, without affecting normal tissues and structures. Therefore, the core invention of the present invention is that the innovatively prepared nail-penetrating delivery carrier can be loaded with antifungal drugs and photosensitizers at the same time, and the antifungal drugs can kill fungi and the phototoxic reaction of photodynamic therapy can simultaneously treat onychomycosis, effectively improving the killing effect on pathogens and reducing the recurrence rate of the disease. In summary, the transfersome preparation for the treatment of onychomycosis provided by the present invention has good nail-penetrating performance, can penetrate deeply under the nail, can improve treatment efficiency, improve bioavailability, reduce the recurrence rate of the disease and the resistance of pathogens to drugs. Compared with traditional transfersomes, the preparation can penetrate the nail plate faster and enter the subungual tissue, greatly shortening the treatment cycle; the raw materials provided by the present invention comply with the provisions of the Chinese Pharmacopoeia and have high safety.

[0036] Furthermore, most of the topical antifungal drugs currently on the market have poor permeability, have developed widespread drug resistance, low cure rate, and high recurrence rate. The present invention selects new antifungal drugs such as ciclopirox, amorolfine, conazole drugs, tazarotene, and tavaborole, and prepares them into transfersome preparations, which can penetrate the nail plate into the subungual tissue to kill pathogens, have high bioavailability, and can effectively treat the cycle and prevent the development of drug resistance.

[0037] The present invention also provides a method for preparing a transfersome-based anti-onychomycosis / photosensitive drug permeation delivery carrier, wherein phospholipids, cholesterol, surfactants, antifungal drugs and / or photosensitizers are dissolved in an organic phase, and the organic solvent is removed by rotary evaporation at a temperature higher than the lipid phase transition temperature to obtain a lipid film, and then an appropriate amount of solution (phosphate buffer solution and ethanol in an appropriate ratio) is added for rotary hydration, and finally the obtained solution is extruded with a polycarbonate membrane to a desired particle size. By optimizing the type and content of each component, a suspension of nano transfersomes for treating onychomycosis is prepared. The process successfully studies a preparation process with the best permeation ability by rationally configuring and optimizing the component content of soybean lecithin, cholesterol, sodium deoxycholate, ethanol, antifungal drugs and / or photosensitizers. Experimental results show that the preparation process of the transfersome preparation provided by the present invention is simple, the conditions are mild, and the safety is high, and it has good application prospects in the field of preparing drugs for treating onychomycosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 A fluorescence microscope image of a frozen section of a nail after the transfersome-based anti-nail fungus / photosensitive drug transnail delivery carrier prepared by the present invention acts on the nail;

[0039] Figure 2 This is a comparison diagram of in vitro permeation curves of the transfersome-based anti-nail fungus / photosensitive drug permeation nail delivery carrier prepared by using different phospholipids as raw materials in the present invention;

[0040] Figure 3 This is a comparison diagram of in vitro permeation curves of the transfersome-based anti-nail fungus / photosensitive drug permeation nail delivery carrier prepared by using different marginal active agents as raw materials in the present invention;

[0041] Figure 4 A comparison diagram of in vitro permeation curves of the anti-nail fungus / photosensitive drug permeation nail delivery carrier based on the transfersome prepared by changing the raw material formula of the present invention;

[0042] Figure 5 It is a comparison diagram of in vitro permeation curves of the anti-nail fungus / photosensitive drug permeation nail delivery carrier based on the transfersome prepared by the present invention when hydrated with different concentrations of ethanol;

[0043] Figure 6 The figure is a comparison chart of in vitro permeation curves of the transfersome-based anti-nail fungus / photosensitive drug permeation nail delivery carrier prepared by using different phospholipids as raw materials in the present invention. DETAILED DESCRIPTION

[0044] In order to enable those skilled in the art to better understand the scheme of the present invention, the technical scheme in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.

[0045] It should be noted that the terms "first", "second", etc. in the specification and claims of the present invention and the above-mentioned drawings are used to distinguish similar objects, and are not necessarily used to describe a specific order or sequence. It should be understood that the data used in this way can be interchanged where appropriate, so that the embodiments of the present invention described herein can be implemented in an order other than those illustrated or described herein. In addition, the terms "including" and "having" and any variations thereof are intended to cover non-exclusive inclusions, for example, a process, method, system, product or device that includes a series of steps or units is not necessarily limited to those steps or units that are clearly listed, but may include other steps or units that are not clearly listed or inherent to these processes, methods, products or devices.

[0046] The present invention is further described in detail below in conjunction with the accompanying drawings:

[0047] The preparation method of the anti-onychomycosis / photosensitive drug permeation delivery carrier based on transfersome disclosed in the present invention comprises: dissolving phospholipids, cholesterol, surfactant, antifungal drug and / or photosensitizer in an organic phase, removing the organic solvent by rotary evaporation at a temperature higher than the lipid phase transition temperature to obtain a lipid film, then adding an appropriate amount of solution (phosphate buffer solution and ethanol in an appropriate ratio) for rotary hydration, and finally extruding the obtained solution with a polycarbonate membrane to a desired particle size. By optimizing the type and content of each component, a suspension of nano transfersomes for treating onychomycosis is prepared.

[0048] Example 1 Preparation of the transfersome preparation (L1) of the present invention

[0049] The preparation method is as follows:

[0050] (1) adding soybean lecithin and cholesterol to 10 mL of chloroform, adding sodium deoxycholate, antifungal drugs and / or photosensitizers to 5 mL of methanol, and sonicating for 3 minutes using a water bath sonicator (ultrasonic power: 70 kHz) to ensure that all components are completely dissolved, thereby obtaining a mixture;

[0051] (2) the mixture was evaporated under reduced pressure using a rotary evaporator at 35°C (speed 100 rpm) to obtain a continuous lipid film after the chloroform and methanol were completely evaporated;

[0052] (3) adding the lipid film to 1 mL of a mixture of phosphate buffer and ethanol solution and ultrasonically treating for 5 minutes to obtain a hydrated preparation, which is the primary drug solution;

[0053] (4) The primary drug solution is passed through a polycarbonate membrane (diameter of 200 nm) in an extruder at 80° C., and this process is repeated 15 to 20 times to obtain the transfersome preparation of the present invention, referred to as L1.

[0054] Based on 1 ml of the transfersome preparation, the concentration of the antifungal drug and / or photosensitizer added was 0.01 mmol / mL.

[0055] Table 1 Raw materials of antifungal drugs and / or photosensitizers, lipids, edge activators and feed concentrations of transfersome preparations of Examples 1 to 9

[0056] Table 1

[0057]

[0058]

[0059] Example 2 Preparation of the transfersome preparation (L2) of the present invention

[0060] Preparation method: The transfersome preparation of the present invention is prepared according to the preparation method of Example 1, referred to as L2, the only difference being that the types of phospholipids and edge activators are replaced according to Table 1, and the feed concentrations of lipids, edge activators, and ethanol in the primary solution are controlled according to Table 1.

[0061] Example 3 Preparation of the transfersome preparation (L3) of the present invention

[0062] Preparation method: The transfersome preparation of the present invention is prepared according to the preparation method of Example 1, referred to as L3, the only difference being that the types of phospholipids and edge activators are replaced according to Table 1, and the feed concentrations of lipids, edge activators, and ethanol in the primary solution are controlled according to Table 1.

[0063] Example 4 Preparation of the transfersome preparation (L4) of the present invention

[0064] Preparation method: The transfersome preparation of the present invention is prepared according to the preparation method of Example 1, referred to as L4, the only difference is that the types of phospholipids and edge activators are replaced according to Table 1, and the feed concentrations of lipids, edge activators, and ethanol in the primary solution are controlled according to Table 1.

[0065] Example 5 Preparation of the transfersome preparation (L5) of the present invention

[0066] Preparation method: The transfersome preparation of the present invention was prepared according to the preparation method of Example 1, referred to as L5, the only difference being that the types of phospholipids and edge activators were replaced according to Table 1, and the feed concentrations of lipids, edge activators, and ethanol in the primary solution were controlled according to Table 1.

[0067] Example 6 Preparation of the transfersome preparation (L6) of the present invention

[0068] Preparation method: The transfersome preparation of the present invention is prepared according to the preparation method of Example 1, referred to as L6, the only difference being that the types of phospholipids and edge activators are replaced according to Table 1, and the feed concentrations of lipids, edge activators, and ethanol in the primary solution are controlled according to Table 1.

[0069] Example 7 Preparation of the transfersome preparation (L7) of the present invention

[0070] Preparation method: The transfersome preparation of the present invention was prepared according to the preparation method of Example 1, referred to as L7, the only difference being that the types of phospholipids and edge activators were replaced according to Table 1, and the feed concentrations of lipids, edge activators, and ethanol in the primary solution were controlled according to Table 1.

[0071] Example 8 Preparation of the transfersome preparation (L8) of the present invention

[0072] Preparation method: The transfersome preparation of the present invention was prepared according to the preparation method of Example 1, referred to as L8, the only difference being that the types of phospholipids and edge activators were replaced according to Table 1, and the feed concentrations of lipids, edge activators, and ethanol in the primary solution were controlled according to Table 1.

[0073] Example 9 Preparation of the transfersome preparation (L9) of the present invention

[0074] Preparation method: The transfersome preparation of the present invention is prepared according to the preparation method of Example 1, referred to as L9, the only difference being that the types of phospholipids and edge activators are replaced according to Table 1, and the feed concentrations of lipids, edge activators, and ethanol in the primary solution are controlled according to Table 1.

[0075] Example 10 Preparation of the transfersome preparation (L10) of the present invention

[0076] In Example 10 of the present invention, the types of lipids and edge activators used in the transfersome preparation and the feed concentrations of lipids, edge activators, ethanol, antifungal drugs and / or photosensitizers are exactly the same as those in Example 2 (L2), with the only difference being that the diameter of the polycarbonate membrane is 100 nm.

[0077] Example 11 Preparation of the transfersome preparation (L11) of the present invention

[0078] In Example 11 of the present invention, the types of lipids and edge activators used in the transfersome preparation and the feed concentrations of lipids, edge activators, ethanol, antifungal drugs and / or photosensitizers are exactly the same as those in Example 2 (L2), with the only difference being that the diameter of the polycarbonate membrane is 400 nm.

[0079] The transfersome preparations prepared in Examples 1 to 11 were subjected to an in vitro nail penetration test, and the test results were compared. The specific test method is as follows:

[0080] Test samples: transfersome preparations L1-L11 prepared in Examples 1-11.

[0081] Experimental steps: The in vitro human nail penetration experiment was conducted using the vertical Franz diffusion cell method. The nail was fixed between the receiving chamber and the supply chamber, and 0.1 mL of each transfersome preparation prepared in Examples 1 to 11 was taken into the supply chamber, and a phosphate buffer solution with a pH of 7.4 was used as the receiving solution. The mixture was diffused by magnetic stirring at 36°C ± 1°C, and the stirring speed was 400 rpm. 0.2 mL of the receiving solution was taken at 2, 4, 6, 8, 24 h and 48 h, and an equal amount of constant temperature fresh receiving solution was immediately added. The HPLC method was used to calculate the cumulative amount of specific drugs permeated through the nail at different times in the receiving solution. The experimental results are shown in the figure below. Figures 2 to 6 as shown in .

[0082] Experimental results:

[0083] from Figure 2 In the test results of the transfersome preparation in vitro nail penetration curve shown in , compared with Example 2, Example 3 and Example 4, under the same penetration time, using soybean lecithin as the raw material, and the other formula ratios and preparation methods are the same, the cumulative penetration amount of Example 2 is significantly higher than that of the transfersome preparation prepared with phosphatidic acid and egg yolk lecithin as raw materials. This shows that soybean lecithin as a raw material further accelerates the in vitro nail penetration rate of the transfersome preparation, and also increases the nail penetration amount, thereby further improving the therapeutic effect on onychomycosis.

[0084] from Figure 3 In the in vitro permeation curve test results of the transfersome preparation shown in , by comparing Example 2 and Example 5, sodium deoxycholate and Tween 80 were selected as marginal active agents respectively under the same permeation time, and the other formula ratios and preparation methods were the same, the permeation rate and permeation amount of the transfersome L2 group and the L5 group were equivalent. Therefore, sodium deoxycholate that meets the safety requirements of the Chinese Pharmacopoeia was selected as the marginal active agent, which would not reduce the therapeutic effect of the transfersome preparation on onychomycosis while improving the safety of the drug.

[0085] from Figure 4In the test results of the transfersome preparation in vitro nail penetration curve shown in , by comparing Example 2, Example 6 and Example 7, under the same penetration time, only the ratio of the raw materials of the transfersome preparation was changed, and the type of formulation and the preparation method were the same, the cumulative penetration amount of Example 7 was significantly increased. This shows that the transfersome preparation prepared according to the ratio method of Example 7 can further improve the in vitro nail penetration rate of antifungal drugs and / or photosensitizers, increase the nail penetration amount, and enhance the therapeutic effect on onychomycosis.

[0086] from Figure 5 In the test results of the transfersome preparation in vitro nail penetration curve shown in , by comparing Example 1, Example 7, Example 8 and Example 9, under the same penetration time, only the content of ethanol in the hydrating agent was changed, and the rest of the formula ratio and preparation method were the same, the cumulative penetration amount of Example 1 was significantly increased. This shows that the transfersome preparation prepared according to the ratio method of Example 1 can further improve the in vitro nail penetration rate of antifungal drugs and / or photosensitizers, increase the nail penetration amount, and enhance the therapeutic effect on onychomycosis.

[0087] from Figure 6 In the test results of the transfersome preparation in vitro nail penetration curve shown in , in Comparative Example 2, Example 10 and Example 11, under the same penetration time, only the diameter of the polycarbonate membrane used in the homogenization treatment was changed, and the other formulations, proportions and preparation methods were the same, the cumulative penetration amount of Example 2 was improved. This shows that the 200 nm diameter polycarbonate membrane treatment will further accelerate the in vitro nail penetration rate of the transfersome preparation, and also increase the nail penetration amount, thereby further improving the therapeutic effect on onychomycosis.

[0088] The above experimental results show that, through continuous optimization of the formula ratio and the production method, the transfersome preparation prepared by the present invention can increase the in vitro permeation rate of antifungal drugs and / or photosensitizers through the nail, increase the permeation amount through the nail, improve the bioavailability of the drugs, and enhance the antifungal efficacy.

[0089] In summary, the present invention provides a transfersome-based anti-onychomycosis / photosensitive drug permeation delivery carrier and its preparation method and application. The transfersome preparation provided by the present invention has good permeation performance and can penetrate deeply under the nail, which can improve the treatment efficiency, improve the bioavailability, reduce the recurrence rate of the disease and the resistance of pathogens to the drug. The transfersome preparation of the present invention is simple, mild, and highly safe, and has good application prospects in the field of preparing drugs for treating onychomycosis.

[0090] The above contents are only for explaining the technical idea of ​​the present invention and cannot be used to limit the protection scope of the present invention. Any changes made on the basis of the technical solution in accordance with the technical idea proposed by the present invention shall fall within the protection scope of the claims of the present invention.

Claims

1. A transfersome-based anti-nail fungus / photosensitive drug perforating nail delivery carrier, It is characterized in that The invention is prepared from raw materials containing the following molar proportions: 0-10.0 parts of antifungal drug, 0-10.0 parts of photosensitizer, 6.0-30.0 parts of phospholipid, 0-2.0 parts of cholesterol and 0-8.0 parts of edge activator; wherein the antifungal drug and photosensitizer cannot be zero at the same time.

2. The anti-onychomycosis / photosensitive drug perforating nail delivery carrier based on transfersome according to claim 1, It is characterized in that The invention is prepared from the following raw materials in molar proportions: 10.0 parts of antifungal drugs and / or photosensitizers, 8.0 parts of phospholipids, 0.5 parts of cholesterol, and 4.0 parts of edge activators.

3. The anti-onychomycosis / photosensitive drug perforating nail delivery carrier based on transfersome according to claim 1 or 2, It is characterized in that The antifungal drug is selected from one or more of ciclopirox, amorolfine, conazole drugs, tazarotene and tavaborole.

4. The anti-onychomycosis / photosensitive drug perforating nail delivery carrier based on transfersome according to claim 1 or 2, It is characterized in that The photosensitizer is selected from one or more of hematoporphyrin monomethyl ether, aloe-emodin, curcumin, ala and 5-aminolevulinic acid.

5. The anti-onychomycosis / photosensitive drug perforating nail delivery carrier based on transfersome according to claim 1 or 2, It is characterized in that The phospholipid is selected from one or more of dipalmitoylphosphatidylcholine, (2,3-dioleoyl-propyl)-trimethylamine, phosphatidic acid, phosphatidylserine, soybean lecithin and egg yolk lecithin.

6. The anti-onychomycosis / photosensitive drug perforating nail delivery carrier based on transfersome according to claim 1 or 2, It is characterized in that The edge activator is selected from one or more of Tween, sodium cholate and sodium deoxycholate.

7. A method for preparing the anti-onychomycosis / photosensitive drug perforating nail delivery carrier based on transfersomes according to any one of claims 1 to 6, It is characterized in that The following steps are involved: 1) dissolving the raw antifungal drug and / or photosensitizer, phospholipid, cholesterol and edge activator in an organic solvent respectively to obtain a mixture; 2) performing rotary evaporation treatment on the organic solvent in the mixture to obtain a mixture film; 3) adding a hydrating medium to the mixture film, performing ultrasonic hydration and annealing treatment at 45° C. to obtain a primary drug solution; 4) The primary drug solution is homogenized to prepare a transfersome-based anti-nail fungus / photosensitive drug trans-nail delivery carrier.

8. The method for preparing the transfersome-based anti-onychomycosis / photosensitive drug perforating nail delivery carrier according to claim 7, Features: In step 1), the organic solvent for dissolving the antifungal drug and / or photosensitizer and edge activator is selected from methanol or ethanol; the organic solvent for dissolving phospholipids and cholesterol is selected from chloroform; In step 2), the mixture is subjected to rotary evaporation in water at 35°C to 65°C under vacuum conditions at a speed of 100 to 120 r / min; In step 3), the hydration medium is a mixture of phosphate buffer solution and ethanol, wherein the proportion of ethanol is 0% to 35%; In step 4), the primary drug solution is homogenized by passing through a polycarbonate membrane of 100 to 400 nm.

9. Use of the transfersome-based anti-onychomycosis / photosensitive drug perforating nail delivery carrier according to any one of claims 1 to 6 in the preparation of a drug for treating onychomycosis, It is characterized in that The medicine is a local therapeutic medicine for onychomycosis.

10. An external preparation for onychomycosis, It is characterized in that The external preparation is prepared from the transfersome-based anti-nail fungus / photosensitive drug perforating nail delivery carrier described in any one of claims 1 to 6, with or without the addition of pharmaceutically acceptable excipients; the external preparation is a perforating nail administration preparation.